| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| TRAIL R2 | HOT TR2-H5229 | Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag, low endotoxin | Human | HEK293 | ![]() | SDS-PAGE | $285.00 100ug | ||
| TRAIL R2 | HOT TR2-H5255 | Human TRAIL R2 / DR5 / TNFRSF10B Protein, Fc Tag, low endotoxin | Human | HEK293 | ![]() | SDS-PAGE | $285.00 100ug | ||
| TRAIL R2 | HOTAvitag TR2-H82E6 | Biotinylated Human TRAIL R2 / DR5 / TNFRSF10B Protein, Avitag™,His Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug | ||
| TRAIL R2 | Cynomolgus TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag, low endotoxin (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $285.00 100ug | |||
| TRAIL R2 | FITC-Labeled Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $330.00 25ug | |||
| TRAIL R2 | Mouse TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag | Mouse | HEK293 | ![]() | SDS-PAGE | $285.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dulanermin (Shanghai GeBaiDe) | Phase 3 Clinical | Shanghai Gebaide Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
| Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) | Phase 3 Clinical | Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd | Neoplasms | Details | |
| TLY-012 | TLY-012 | Phase 1 Clinical | Theraly Fibrosis | Fibrosis; Liver Cirrhosis; Pancreatitis; Pancreatitis, Chronic; Scleroderma, Systemic | Details |
| BI-905711 | BI-905711 | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Cholangiocarcinoma; Gastrointestinal Neoplasms; Pancreatic Neoplasms | Details |
| Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) | CTB-006 | Phase 1 Clinical | Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd | Solid tumours | Details |
| Ozekibart | JCT-205; INBRX-109 | Phase 1 Clinical | Inhibrx Inc | Adenocarcinoma | Details |
| TRAILR2/CDH3 bispecific antibody (Boehringer Ingelheim) | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Neoplasms | Details | |
| RC-248 | RC-248; RC248 | Phase 1 Clinical | Solid tumours | Details | |
| IBI-3004 | IBI-3004; IBI3004 | Phase 1 Clinical | Colorectal Neoplasms; Solid tumours | Details | |
| Oba-01 | Oba-01; Oba01 | Phase 1 Clinical | Yantai Heyuanaidisi Biomedical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Aponermin | Approved | Beijing Shadong Biotech Co Ltd | 沙艾特, Shaite | Mainland China | Multiple Myeloma | Wuhan Hiteck Biological Pharma Co Ltd | 2023-11-02 | Multiple Myeloma | Details |